PUBLIC COMPANY
save$LEGNLegend Biotech Corp
$LEGN24.29+3.80%Somerset, NJ, USupdated 7d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- 10 companies hiring in New JerseyLooking for a biopharma job in New Jersey? Jobs on BioSpace increased year over year in October, and there are hundreds of open positions posted now.biospace · 5d ago
- China has a clear shot to 2030 goals, though economic, cultural barriers remainTo grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.biospace · 6d ago
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 7d ago
- Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturingThe BioSpace 40 Under 40 honoree helped steer Forge’s sale to Ajinomoto. Now, Samantha Piteri-Molina sees opportunities in AI-driven analytics and Ohio’s gene therapy ecosystem—with a responsibilit…biospace · 10d ago
- The top 12 companies hiring in biopharma nowAverage jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire.biospace · 12d ago
- 6 potential blockbusters that could pave China’s path to 2030 ambitionsIn its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…biospace · 13d ago
- Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune pushSail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in terms of venture capital fundraising in the third quarter.biospace · 14d ago
- Most new drugs are still too costly at launch, ICER saysA new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.biopharma_dive · 27d ago
- Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior splitPlus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…endpoints · 1mo ago
- J&J, Legend tout long-term survival benefits for Carvykti in multiple myelomaTen patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.biospace · 1mo ago
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that